Drug companies tell us, Congress & the courts Medicare price negotiation will badly undercut profit and innovation. But they tell investors a different story: "We'll be fine." The IRA actually strikes a balance to get lower prices & protect innovation. https://t.co/VvxrEsYKkR

The Hill@thehill

2 years ago

Drug companies confident Medicare price deals won’t hit bottom lines https://t.co/FqR3REtsQK

STAT@statnews

2 years ago

Patients and their families lose if they don't have access to lower-cost biosimilars, and taxpayers lose when Medicare and other government medical programs can't realize existing cost savings. https://t.co/tjVBGOKtnb